- World Pharma News Home » Product » Genzyme Files Applications for Approval of Mozobil in the United States and Europe
(a free service delivered by FeedBurner)
Genzyme Corporation (Nasdaq: GENZ) announced that it has submitted marketing applications in both the United States and the European Union for Mozobilâ„¢ (plerixafor), a product candidate intended to enhance mobilization of hematopoietic stem cells for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma. The company has requested priority review of its U.S. application and, if granted, Mozobil could be approved by the end of this year. European approval is expected in 2009. Additional global applications in up to 60 countries are expected to follow.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments